Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs ResMed Inc. — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $14.85 (market cap $7.07B), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.5× Norwegian Cruise Line Holdings Ltd's market cap, and ResMed Inc. pays a 1.19% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | RMD | |
|---|---|---|
Market Cap | $7.07B | $31.89B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $283.28 |
52-Week Low | $14.79 | $182.82 |
Enterprise Value | $21.88B | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals but attractive valuation metrics including a P/E of 9.33 and P/S of 0.74. The company has beaten earnings estimates for three consecutive quarters, though Q3 2026 faces a higher bar at $0.89 EPS. Recent news highlights fuel cost pressures from rising oil prices, contributing to the stock's recent decline despite positive operational developments like new waterpark openings and fleet expansion.
NCLH presents a value opportunity with strong profitability metrics (36.73% ROE) and analyst consensus price target of $20.25 (32% upside), but faces significant risks from fuel cost volatility, high leverage (debt-to-asset ratio 64.79%), and competitive pressure. The company's turnaround plan focusing on cost controls and fleet optimization must overcome macroeconomic headwinds to drive sustained recovery.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
